$1,000 follows their calls into $851
- Win rate
- 45%
- Streak
- —
- Best call
- No call read in the last 30 days
Track record building
- Peak #156
- 5 ranked closes
- Longest streak 4
$1,000 follows their calls into $851
StockPursuit@Stock_PursuitI've been working on Part 2 of the Infinity Natural Resources $INR research. I'm going more into the financials, credit ratings and doing an an appalachian basin natural gas & oil E&P peer relative valuation. The shorts are in this one pretty heavy. Around 20% of the float is
StockPursuit@Stock_PursuitJust being somewhat bullish on natural gas prices there's value at face value in a lot of oil and gas E&P stocks in the Appalacian Basin. With Infinity Natural Resources $INR at $13.00 it's trading at just a P/E of 5. Trailing twelve month EBITDAX is $366 mil. The current

StockPursuit@Stock_PursuitThe recent Anthropic Mythos 5 model that was banned by the government showed some amazing new abilities. One of them was in life sciences research specifically in drug design. I initially saw this as being bullish for the pharma/biopharma industry. I don't think it is
StockPursuit@Stock_Pursuit$VIA Via Transportation it just keeps truckin'

StockPursuit@Stock_PursuitI found Via Transportation $VIA from the most recent value screening. Via obviously isn't deep value, and I frankly wasn't expecting to find good, fairly liquid actual deep value. It's much harder to find quality net-nets, sub NTAV these days. The strong balance sheet focus

StockPursuit@Stock_Pursuit$RXRX Recursion Pharma Technical base bottom confirming and the stock has momentum. Good volume on the level break.

StockPursuit@Stock_PursuitMultiple market research firms predict the AI-genomics industry will have 38%-45% CAGR through the early 2030s. Big pharma and biopharma are spending billions on AI-driven platforms across their entire scope of business. Recursion Pharmaceuticals $RXRX has a drug discovery
